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More robust identification of putative 
molecular targets for the development of 
novel therapeutics is a logical outcome 
of the post-genomic age of molecular 
medicine. Undoubtedly the concept of 
personalized medicine is becoming a real-
ity (Hamburg and Collins, 2010), and in 
this scenario, the pharmacological sci-
ences are ideally positioned to have a huge 
impact on the continued development of 
this field; specifically as it relates to the 
advent of mechanism-based, personalized 
therapeutics. In fact, the incredible rate of 
technology development and the parallel 
increase in our capacity to harness and 
apply the inordinate amount of infor-
mation generated in the wake of these 
advancements creates tremendous chal-
lenges for our field, but also, enormous 
translational research opportunities.
The purpose of this article is to briefly 
review the Grand Challenge for Integrative 
and Regenerative Pharmacology, and to 
highlight how meeting the challenge will 
ensure our active participation in this 
exciting, and quite frankly unprecedented 
era of translational scientific endeavor. 
The Grand Challenge is codified below in 
general terms, but without question it will 
require a multi/interdisciplinary collabo-
rative effort, on a global basis, to be suc-
cessful. Furthermore, it is clear that each of 
the three aspects of this Grand Challenge 
could themselves be the subject of an 
entire review article. Herein we provide 
only a general conceptual framework to 
familiarize the interested reader with the 
overall topic.
The Grand Challenge for Integrative and 
Regenerative Pharmacology is three-fold:
1. To utilize Integrative Pharmacology 
(studies ranging from in vivo whole 
animal pharmacology/toxicology to 
complex in vitro and ex vivo systems) to 
obtain improved insight into  relevant 
mechanisms of end organ/tissue 
 dysfunction (i.e., target validation) as 
well as mechanisms of tissue regenera-
tion, repair, and replacement.
2. To utilize cutting edge drug delivery 
technologies to improve localized deli-
very of therapeutic drug concentra-
tions/effects, and furthermore, enhance 
specificity with respect to the cellular 
and subcellular targets/compartments 
of interest.
3. To leverage both 1 and 2 to create a 
new generation of therapies for impro-
ved symptomatic treatment of disease 
(i.e., fewer side/off-target effects due 
to improved MOA, enhanced locali-
zation, and cellular/subcellular spe-
cificity), and moreover, development 
of  transformational curative therapies 
through the establishment of the prin-
ciples of regenerative pharmacology.
Utilization of integrative 
Pharmacology StrategieS
As noted in our mission statement, the 
purpose of this Specialty Journal is to 
emphasize the importance of complex 
systems and whole animal research for the 
discovery of novel mechanisms of action 
and novel therapeutic entities leading to 
the discovery and development of new 
treatments for human disease. Implicit in 
this approach is the necessity to coordinate 
information obtained in complex in vitro 
and ex vivo systems with data obtained 
on rodent and large animal models that 
recapitulate relevant aspects of the cor-
responding human clinical conditions. 
Such an endeavor is intrinsically multi-
disciplinary, and pharmacologists will 
need to reach out to their colleagues in 
systems biology, bioinformatics, math-
ematics, engineering, etc., to be success-
ful. As recently pointed out by Dr. Michael 
Rogers at NIGMS:
“At this time, NIGMS has a substantial 
grant investment in pharmacology and 
in systems biology, but we have not 
seen a great deal of activity integrating 
 pharmacology with systems biology to 
benefit drug  discovery and the understand-




In this regard, NIGMS has recently 
sponsored workshops to increase awareness 
of this critical effort, and to promote the 
required scientific interactions/collabora-
tions. Further details about this important 
effort are available in a recent publication 
(Berg et al., 2010). The complexities of the 
“Integrative” or “Systems” pharmacology 
process are well beyond the focused nature 
of this brief report but have been elegantly 
addressed in another recent publication 
(Dollery, 2010). Importantly, the parallel 
development of novel training programs for 
preparing the next generation of researchers 
to participate in this aspect of the Grand 
Challenge has also recently been described 
(Sobie et al., 2010).
Without question, utilization of the 
resources and infrastructure resulting from 
this enormous effort represents an important 
tool with which to address this aspect of the 
Grand Challenge. Certainly, this collabora-
tive approach falls well within the scope of 
Integrative and Regenerative Pharmacology. 
Encouraging examples of how a systems 
approach (i.e., multiscale analysis and 
mathematical modeling) may contribute 
to the development of novel therapeutics 
can be found with respect to recently pub-
lished mathematical models of integrated 
calcium homeostasis (Peterson and Riggs, 
2010), as well as with respect to the cardiac 
physiome project (Bassingthwaighte et al., 
2009). Applications even more specific to 
Integrative Pharmacology have also recently 
been reviewed (Hendriks, 2010); where the 
importance of analysis of functional pathway 
pharmacology has been emphasized. That is, 
the development of computational models 
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in thinking from developing drugs whose 
primary purpose is to treat symptoms (i.e., 
palliative) to developing drugs whose goal 
is to cure disease. This journal seems an 
ideal venue for outlining the possibilities, 
describing the journey, and publishing the 
results. The Integrative and Regenerative 
Pharmacology specialty journal hopes 
to keeps its finger on the pulse of the 
 achievement of these worthy goals.
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the pursuit of Integrative and Regenerative 
Pharmacology, wherein they could be utilized 
not only to provide enhanced symptomatic 
relief of end organ disease/pathology, but to 
modulate cell and tissue formation and func-
tion as well. For example, the use of nano-
particles (both polymer and lipid based) to 
enhance delivery of both genes (Pack et al., 
2005) and other difficult to formulate/deliver 
therapeutics, such as those used for the treat-
ment of cancer (Drummond et al., 2009) have 
recently been described. Furthermore, nano-
carriers can be modified in numerous ways 
to cater to both the therapeutic indication, 
as well as the environment in the tissue of 
interest (Torchilin, 2009).
Delivery of imProveD 
SymPtomatic treatmentS anD 
tranSformative cUrative 
theraPieS
The ultimate goal of Integrative and 
Regenerative Pharmacology is improved 
therapies for human disease. The last 
aspect of the Grand Challenge therefore 
is to optimize the alignment of Integrative 
and Regenerative Pharmacology with mod-
ern drug delivery technologies and systems 
pharmacology approaches. This will surely 
require a paradigm shift in the way that 
integrative pharmacologists think about 
developing novel therapies; specifically, a 
shift toward vastly improved symptomatic 
treatment of disease, and moreover, to the 
development of truly curative pharmaco-
therapies. For example, when there is suf-
ficient viable tissue remaining, many new 
pharmacological strategies that leverage 
the newest developments in systems phar-
macology and drug delivery systems can be 
envisioned for the improved treatment of 
disease/pathology, including Regenerative 
Pharmacology. However, when there is a 
paucity of viable tissue, or none at all, tra-
ditional pharmacotherapy will not suffice, 
and other approaches, such as tissue engi-
neering and advanced regenerative medi-
cine technologies (also under the auspices 
of Regenerative Pharmacology) will need 
to be implemented.
In summary, as with all of the medical 
sciences, there are many challenges ahead in 
Integrative and Regenerative Pharmacology. 
Nonetheless, it is time for a seismic move 
that can account for the  complexity of signal 
transduction networks. The rationale for this 
latter approach is that improved target vali-
dation (and improved clinical translation of 
preclinical results) should take into account 
both upstream and downstream pathway 
events, as well as the impact of the disease 
process, per se, on the pharmacological target 
of interest. The implications of this “systems” 
approach to Integrative and Regenerative 
Pharmacology are straightforward.
imProveD Utility anD enhanceD 
SPecificity of theraPeUtic DrUg 
Delivery SyStemS
Another aspect of the Grand Challenge is the 
application of drug delivery technologies. 
Development and implementation of these 
cutting edge technologies clearly requires 
multi/interdisciplinary collaboration. Not 
surprisingly, modern drug delivery systems 
derive from technologies developed at the 
boundaries of nanotechnology, materials 
science, chemistry, and engineering. In this 
regard, a systematic and comprehensive 
review of modern drug delivery systems 
would be problematic even in a lengthy report 
dedicated only to that subject, in large part 
because these systems comprise a wide array 
of mostly application-specific technologies. 
Notwithstanding this, the goal of all of these 
technologies is to overcome a common set 
of barriers that limit the effectiveness of tra-
ditional pharmacotherapy, and moreover, 
extend the realm of deliverable therapeu-
tic agents to a wider array of compounds, 
as well as gene therapies. The first of these 
barriers is the issue of vascular extravasation 
(Fukumura et al., 2010). That is, ensuring 
that the drug/compound/gene of interest 
leaves the systemic circulation to enter the 
tissue(s) of interest. Of course, drug delivery 
systems that utilize transdermal, injection, or 
direct implantation routes are by definition 
less dependent on extravasation. However, 
once the compound/technology of interest 
has been delivered to the tissue of interest, 
there are still local diffusion barriers in the 
tissue, and then, there is still the issue of cel-
lular and subcellular targeting specificity. All 
of these issues are currently being addressed 
by a diverse group of labs on a worldwide 
basis. There are clearly major implications 
of the availability of these technologies to 
